Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lessened its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 5.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,921,762 shares of the company's stock after selling 116,779 shares during the period. Envestnet Asset Management Inc. owned 0.17% of Teva Pharmaceutical Industries worth $29,537,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TEVA. Oarsman Capital Inc. bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $29,000. Golden State Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $39,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $44,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at approximately $54,000. Finally, Versant Capital Management Inc lifted its stake in Teva Pharmaceutical Industries by 437.8% in the 1st quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock valued at $81,000 after acquiring an additional 4,312 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TEVA. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Bank of America upped their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 target price for the company. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Finally, Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target on the stock. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Stock Down 1.5%

NYSE TEVA traded down $0.25 during trading on Friday, hitting $16.07. The company's stock had a trading volume of 4,529,178 shares, compared to its average volume of 10,300,625. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. The company has a market cap of $18.43 billion, a PE ratio of -13.97, a P/E/G ratio of 0.94 and a beta of 0.60. The business's 50 day simple moving average is $17.02 and its 200-day simple moving average is $17.02. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The company had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. Teva Pharmaceutical Industries's quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the business earned $0.48 earnings per share. On average, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the transaction, the executive vice president owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This represents a 38.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.